Background
==========

Hepatocellular carcinoma (HCC) is one of the most common carcinomas in the world, especially in China. Most of the HCC in China is hepatitis B virus (HBV)-related which is caused by the high HBV infection rates.[@b1-tcrm-13-191]--[@b3-tcrm-13-191] Although the overall survival of patients with HBV-related HCC had been improved, the survival still remains unsatisfactory.[@b4-tcrm-13-191],[@b5-tcrm-13-191] Therefore, it is very important to find novel prognostic markers and potential therapeutic target for HBV-related HCC.

Previous studies have shown that AP-1 transcription factor c-Jun is overexpressed in many human cancers.[@b6-tcrm-13-191]--[@b8-tcrm-13-191] RING domain AP-1 coactivator-1 (RACO-1) is a c-Jun coactivator that is regulated by growth factor signaling. RACO-1 depletion decreased the expression of several AP-1 target genes, such as *cdc42*, *cyclinD1*. RACO-1 also has an important relationship with Wnt signaling and Ras.[@b9-tcrm-13-191],[@b10-tcrm-13-191] However, the role of RACO-1 in HBV-related HCC has not been demonstrated. Whether RACO-1 has an effect on the prognosis of HBV-related HCC is still unknown. This study aimed to investigate the effects of RACO-1 on HBV-related HCC and find out the relationship between RACO-1 and the prognosis of HBV-related HCC.

Methods
=======

Patients and specimens
----------------------

In this study, HCC was diagnosed and staged according to both the Barcelona Clinic Liver Cancer (BCLC) stage system and International Union for Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) stage system. HCC and the adjacent non-tumor liver tissue (ANLT) specimens were obtained from 136 HBV-related HCC patients during surgical resection without any preoperative treatment at the Department of Hepatobiliary Surgery, Shaoxing Second Hospital, and Department of Surgery, Zhuzhou Clinical Institute, Central South University (CSU) School of Medicine from March 2008 to March 2014. The follow-up status and any recurrence were regularly updated in the database for each patient. Our research was in compliance with the Helsinki Declaration. Prior written informed consent was obtained from all patients. The ethics committees of Shaoxing Second Hospital, Zhuzhou Clinical Institute of CSU, and the Fourth Affiliated Hospital of Zhejiang University School of Medicine gave ethics approval for this study and approved the consents. Before the operations, we evaluated the complete blood count, liver function, computed tomography (CT) scan of liver and other tests if necessary. Liver resection was undertaken in patients with Pugh--Child grades A or B.

Immunohistochemistry (IHC)
--------------------------

Formalin-fixed paraffin sections were stained for RACO-1 using anti-human RACO-1 antibody (Abcam, Cambridge, UK). The expression level of RACO-1 was scored as: 1, 1%--25% positive; 2, 26%--50% positive; 3, \>50% positive. The protein expression of RACO-1 was thus considered low expression if scored 1; score 2 or 3 was considered as high expression. Correlation between RACO-1 expression and clinicopathologic features of HBV-related HCC were analyzed in both the cohorts.

Statistical analysis
--------------------

Data in the study was analyzed by the Statistical Package for the Social Sciences (SPSS) 19 for Windows (SPSS Inc., Chicago, IL, USA). Fisher's exact test was used for the statistical analysis of categorical data, whereas independent *t*-tests were used for continuous data. The log-rank test was used to compare the overall and disease-free survival. The Cox proportional hazards regression model was established to identify factors that were independently associated with the survival of HCC patients. *P*\<0.05 was considered to be statistically significant.

Results
=======

Clinical features of patients and the correlations of RACO-1 expression with the clinical characteristics of HBV-related HCC
----------------------------------------------------------------------------------------------------------------------------

A total of 136 tissue samples of HBV-related HCC were detected by IHC, including 76 patients in training cohort and 60 patients in validation cohort ([Figure 1](#f1-tcrm-13-191){ref-type="fig"}). There is no significant difference between training cohort and validation cohort ([Table 1](#t1-tcrm-13-191){ref-type="table"}). RACO-1 expression was significantly high in HBV-related HCC tissues in both training cohort and validation cohort ([Tables 2](#t2-tcrm-13-191){ref-type="table"} and [S1](#SD1-tcrm-13-191){ref-type="supplementary-material"}). It was found that RACO-1 expression negatively correlates with capsular in both training cohort and validation cohort (*P*=0.039; 0.041). The RACO-1 expression in training cohort was positively related to liver cirrhosis (*P*=0.046), tumor number (*P*=0.046), vascular invasion (*P*=0.021), UICC stage (*P*=0.006), and BCLC stage (*P*=0.041) ([Table 2](#t2-tcrm-13-191){ref-type="table"}). While in validation cohort, RACO-1 expression was positively related to liver cirrhosis (*P*=0.041), tumor number (*P*=0.046), vascular invasion (*P*=0.005), UICC stage (*P*=0.048), and BCLC stage (*P*=0.003) ([Table S1](#SD1-tcrm-13-191){ref-type="supplementary-material"}).

Correlations of RACO-1 expression with the overall survival of HBV-related HCC
------------------------------------------------------------------------------

Overall survival was analyzed according to the expression of RACO-1 both in training cohort and validation cohort. The high level of RACO-1 had worse overall survival rates in both the training cohort and the validation cohort (*P*\<0.001; *P*\<0.001) ([Figure 2](#f2-tcrm-13-191){ref-type="fig"}). In training cohort, we found that RACO-1 expression is one of the important prognostic factors ([Table 3](#t3-tcrm-13-191){ref-type="table"}). The multivariate cox regression analysis showed the same result in the training cohort. RACO-1 expression is one of the independent prognostic factors for overall survival of HBV-related HCC. Furthermore, in the validation cohort, the results from the univariate cox regression analysis associated with overall survival also indicated that RACO-1 expression is one of the important prognostic factors ([Table S2](#SD2-tcrm-13-191){ref-type="supplementary-material"}). The multivariate cox regression analysis also showed that RACO-1 is one of the independent prognostic factors for overall survival of HBV-related HCC.

Correlations of RACO-1 expression with the disease-free survival of HBV-related HCC
-----------------------------------------------------------------------------------

Disease-free survival was detected in both training cohort and validation cohort. RACO-1 high expression group had worse disease-free survival in both training cohort and validation cohort (*P*\<0.001; *P*\<0.001) ([Figure 2](#f2-tcrm-13-191){ref-type="fig"}). In training cohort, it was found that RACO-1 expression is one of the important factors together with UICC/AJCC stage, and so on ([Table 4](#t4-tcrm-13-191){ref-type="table"}). The multivariate cox regression analysis showed RACO-1 expression together with vascular invasion, UICC/AJCC stage and BCLC stage were independent prognostic factors for disease-free survival of HBV-related HCC. In validation cohort, the result is similar. RACO-1 expression together with UICC/AJCC stage and some other factors were important for prognosis ([Table S3](#SD3-tcrm-13-191){ref-type="supplementary-material"}). The multivariate cox regression analysis showed that RACO-1 expression is one of the independent prognostic factors for disease-free survival of HBV-related HCC.

Discussion
==========

This study aimed to investigate the effects of RACO-1 on HBV-related HCC. Interestingly, it was found that RACO-1 expression was significantly high in HBV-related HCC tissues in both training cohort and validation cohort. RACO-1 high expression group had worse overall and disease-free survival rates than the low expression group in both training cohort and validation cohort. This indicates that RACO-1 may play an important role in the development of HBV-related HCC and could be a potential target for the treatment of HCC. However, we still do not know the mechanism. This part of work remains to be done in our further research.

Subsequently, the RACO-1 expression was positively related to liver cirrhosis in both training cohort and validation cohort. Most of HCC occurring in China would pass through three steps: HBV infection, liver cirrhosis, and HCC.[@b11-tcrm-13-191]--[@b15-tcrm-13-191] RACO-1 may play an important role in the development of HCC by regulating HBV-related cirrhosis.

Interestingly, it is found that RACO-1 expression also has a significant relationship with tumor number, capsular formation, and vascular invasion. Tumor number together with capsular formation and vascular invasion play an important role in the invasion and metastasis of HCC.[@b16-tcrm-13-191]--[@b18-tcrm-13-191] The present study also showed that RACO-1 expression together with vascular invasion, UICC/AJCC stage, and BCLC stage were independent prognostic factor for overall and disease-free survival of HBV-related HCC. Accordingly, it was speculated that RACO-1 may play an important role in the invasion and metastasis of HBV-related HCC. New research into the potential mechanism of RACO-1 in the invasion and metastasis of HCC has been undertaken.

Conclusion
==========

In conclusion, it has been shown for the first time that increased expression of RACO-1 is related to worse overall survival in patients with HBV-related HCC. The study implicates RACO-1 as a novel prognostic marker and a potential therapeutic target for HBV-related HCC.

Supplementary materials
=======================

###### 

Correlations between RACO-1 expression and clinicopathologic variables of 60 cases of HBV-related HCC in validation cohort

  Clinicopathologic variables   Patients (n)   RACO-1 expression levels        
  ----------------------------- -------------- -------------------------- ---- -----------
  Gender                                                                       
   Female                       19             9                          10   0.133
   Male                         41             11                         30   
  Age (years)                                                                  
   ≤60                          50             15                         35   0.098
   \>60                         10             5                          5    
  Liver cirrhosis                                                              
   Presence                     31             6                          25   **0.041**
   Absence                      29             14                         15   
  Tumor number                                                                 
   Solitary                     30             14                         16   **0.046**
   Multiple                     30             6                          24   
  Tumor size                                                                   
   ≤5 cm                        28             8                          20   0.688
   \>5 cm                       32             12                         20   
  Capsular formation                                                           
   Presence                     29             14                         15   **0.041**
   Absence                      31             6                          25   
  Vascular invasion                                                            
   Presence                     26             3                          23   **0.005**
   Absence                      34             17                         17   
  Edmondson-Steiner grade                                                      
   Low grade (I--II)            32             12                         20   0.721
   High grade (III--IV)         28             8                          20   
  UICC/AJCC stage                                                              
   I                            25             12                         13   **0.048**
   II--III                      35             8                          27   
  BCLC stage                                                                   
   0--A                         27             15                         12   **0.003**
   B--C                         33             5                          28   

**Note:** *P*\<0.05 was considered to be statistically significant, and the significant values are shown in bold.

**Abbreviations:** AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; UICC, International Union for Cancer Control; RACO-1, RING domain AP-1 coactivator-1; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.

###### 

Univariable and multivariable analysis of factors in validation cohort associated with overall survival

  Variables                 Patients (n)   Univariable analysis   Multivariable analysis                          
  ------------------------- -------------- ---------------------- ------------------------ ---------------------- -----------
  Gender                                                                                                          
   Female                   19             1                                                                      
   Male                     41             1.743 (0.646--4.703)   0.274                    NA                     NA
  Age (years)                                                                                                     
   ≤60                      50             1                                                                      
   \>60                     10             1.264 (0.842--1.898)   0.418                    NA                     NA
  Liver cirrhosis                                                                                                 
   Absent                   31             1                                                                      
   Present                  29             1.208 (0.367--3.976)   0.528                    NA                     NA
  Tumor number                                                                                                    
   Solitary                 30             1                                                                      
   Multiple                 30             2.683 (0.732--4.156)   0.089                    NA                     NA
  Tumor size                                                                                                      
   ≤5 cm                    28             1                                                                      
   \>5 cm                   32             1.874 (0.876--4.009)   0.427                    NA                     NA
  Capsular formation                                                                                              
   Presence                 29             1                                               1                      
   Absence                  31             2.287 (1.732--3.020)   **0.048**                1.327 (0.931--1.891)   0.076
  Vascular invasion                                                                                               
   Absent                   26             1                                               1                      
   Present                  34             2.359 (1.265--4.400)   **0.029**                2.539 (1.873--3.442)   **0.021**
  Edmondson-Steiner grade                                                                                         
   Low grade (I--II)        32             1                                                                      
   High grade (III--IV)     28             1.325 (0.856--1.663)   0.068                    NA                     NA
  UICC/AJCC stage                                                                                                 
   I                        25             1                                               1                      
   II--III                  35             2.464 (1.905--3.187)   **0.021**                2.643 (1.735--4.026)   **0.031**
  BCLC stage                                                                                                      
   0--A                     27             1                                               1                      
   B--C                     33             2.532 (1.456--4.403)   **0.039**                1.753 (1.231--2.496)   **0.041**
  RACO-1 expression                                                                                               
   Low                      20             1                                               1                      
   High                     40             1.936 (1.533--4.238)   **0.031**                2.052 (1.435--2.934)   **0.029**

**Note:** *P*\<0.05 was considered to be statistically significant; significant values are shown in bold.

**Abbreviations:** AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; UICC, International Union for Cancer Control; RACO-1, RING domain AP-1 coactivator-1; HR, hazard ratio; CI, confidence interval.

###### 

Univariable and multivariable analysis of factors in validation cohort associated with disease-free survival

  Variables                 Patients (n)   Univariable analysis   Multivariable analysis                          
  ------------------------- -------------- ---------------------- ------------------------ ---------------------- -----------
  Gender                                                                                                          
   Female                   19             1                                                                      
   Male                     41             1.328 (0.395--3.542)   0.329                    NA                     NA
  Age (years)                                                                                                     
   ≤60                      50             1                                                                      
   \>60                     10             1.681 (0.787--2.252)   0.535                    NA                     NA
  Liver cirrhosis                                                                                                 
   Absent                   31             1                                                                      
   Present                  29             1.268 (0.688--3.127)   0.631                    NA                     NA
  Tumor number                                                                                                    
   Solitary                 30             1                                                                      
   Multiple                 30             2.281 (0.868--3.689)   0.535                    NA                     NA
  Tumor size                                                                                                      
   ≤5 cm                    28             1                                                                      
   \>5 cm                   32             1.431 (0.627--2.758)   0.595                    NA                     NA
  Capsular formation                                                                                              
   Presence                 29             1                                               1                      
   Absence                  31             1.658 (1.217--3.268)   **0.045**                1.212 (0.919--3.278)   0.078
  Vascular invasion                                                                                               
   Absent                   26             1                                               1                      
   Present                  34             2.215 (1.364--3.182)   **0.008**                2.378 (1.468--4.271)   **0.013**
  Edmondson-Steiner grade                                                                                         
   Low grade (I--II)        32             1                                                                      
   High grade (III--IV)     28             1.188 (0.890--2.685)   0.275                    NA                     NA
  UICC/AJCC stage                                                                                                 
   I                        25             1                                               1                      
   II--III                  35             2.209 (1.338--3.817)   **0.017**                2.129 (1.210--4.644)   **0.039**
  BCLC stage                                                                                                      
   0--A                     27             1                                                                      
   B--C                     33             1.367 (1.121--3.017)   **0.022**                1.415 (1.123--3.684)   **0.037**
  RACO-1 expression                                                                                               
   Low                      20             1                                               1                      
   High                     40             2.175 (1.198--4.128)   **0.016**                2.156 (1.338--3.985)   **0.028**

**Note:** *P*\<0.05 was considered to be statistically significant; significant values are shown in bold.

**Abbreviations:** AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; UICC, International Union for Cancer Control; RACO-1, RING domain AP-1 coactivator-1; HR, hazard ratio; CI, confidence interval.
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![Immunohistochemistry of RACO-1 expression in HBV-related HCC tissues.\
**Notes:** (**A**--**D**) These representative images show negative control-isotype control (scored as 0, **A**), 1%--25% of cancer cells (scored as 1+, **B**), 26%--50% of cancer cells (scored as 2+, **C**), and \>51% of cancer cells (scored as 3+, **D**); original magnification ×400.\
**Abbreviations:** RACO-1, RING domain AP-1 coactivator-1; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](tcrm-13-191Fig1){#f1-tcrm-13-191}

![Correlations of RACO-1 expression with the overall survival and disease-free survival of HBV-related HCC.\
**Notes:** (**A**) Overall survival was analyzed according to the expression of RACO-1 in training cohort (*P*\<0.001). (**B**) Kaplan--Meier survival curves of disease-free survival in training cohort (*P*\<0.001). (**C**) Overall survival was analyzed according to the expression of RACO-1 in validation cohort (*P*\<0.001). (**D**) Kaplan--Meier survival curves of disease-free survival in validation cohort (*P*\<0.001).\
**Abbreviations:** RACO-1, RING domain AP-1 coactivator-1; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](tcrm-13-191Fig2){#f2-tcrm-13-191}

###### 

Clinicopathologic variables of training cohort and validation cohort

  Clinicopathologic variables   Training cohort (n)   Validation cohort (n)   *P*-value
  ----------------------------- --------------------- ----------------------- -----------
  Gender                                                                      
   Female                       24                    19                      0.642
   Male                         52                    41                      
  Age (years)                                                                 
   ≤60                          60                    50                      0.665
   \>60                         16                    10                      
  Liver cirrhosis                                                             
   Presence                     40                    31                      0.645
   Absence                      36                    29                      
  Tumor number                                                                
   Solitary                     36                    30                      0.168
   Multiple                     40                    30                      
  Tumor size                                                                  
   ≤5 cm                        36                    28                      0.635
   \>5 cm                       40                    32                      
  Capsular formation                                                          
   Presence                     35                    29                      0.804
   Absence                      41                    31                      
  Vascular invasion                                                           
   Presence                     30                    26                      0.715
   Absence                      46                    34                      
  Edmondson-Steiner grade                                                     
   Low grade (I--II)            45                    32                      0.803
   High grade (III--IV)         31                    28                      
  UICC/AJCC stage                                                             
   I                            30                    25                      0.682
   II--III                      46                    35                      
  BCLC stage                                                                  
   0--A                         37                    27                      0.811
   B--C                         39                    33                      

**Abbreviations:** AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; UICC, International Union for Cancer Control.

###### 

Correlations between RACO-1 expression and clinico-pathologic variables of 76 cases of HBV-related HCC in training cohort

  Clinicopathologic variables   Patients (n)   RACO-1 expression levels   *P*-value   
  ----------------------------- -------------- -------------------------- ----------- -----------
  Gender                                                                              
   Female                       24             7                          17          0.502
   Male                         52             17                         35          
  Age (years)                                                                         
   ≤60                          60             19                         41          0.678
   \>60                         16             5                          11          
  Liver cirrhosis                                                                     
   Presence                     40             7                          33          **0.046**
   Absence                      36             17                         19          
  Tumor number                                                                        
   Solitary                     36             17                         19          **0.046**
   Multiple                     40             7                          33          
  Tumor size                                                                          
   ≤5 cm                        36             9                          27          0.217
   \>5 cm                       40             15                         25          
  Capsular formation                                                                  
   Presence                     35             17                         18          **0.039**
   Absence                      41             7                          34          
  Vascular invasion                                                                   
   Presence                     30             3                          27          **0.021**
   Absence                      46             21                         25          
  Edmondson-Steiner grade                                                             
   Low grade (I--II)            45             11                         34          0.185
   High grade (III--IV)         31             13                         18          
  UICC/AJCC stage                                                                     
   I                            30             17                         13          **0.006**
   II--III                      46             7                          39          
  BCLC stage                                                                          
   0--A                         37             18                         19          **0.041**
   B--C                         39             6                          33          

**Note:** *P*\<0.05 was considered to be statistically significant; significant values are shown in bold.

**Abbreviations:** AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; UICC, International Union for Cancer Control; RACO-1, RING domain AP-1 coactivator-1; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.

###### 

Univariable and multivariable analysis of factors in training cohort associated with overall survival

  Variables                 Patients (n)   Univariable analysis   Multivariable analysis                          
  ------------------------- -------------- ---------------------- ------------------------ ---------------------- -----------
  Gender                                                                                                          
   Female                   24             1                                                                      
   Male                     52             1.654 (0.689--6.426)   0.268                    NA                     NA
  Age (years)                                                                                                     
   ≤60                      60             1                                                                      
   \>60                     16             1.125 (0.895--2.102)   0.468                    NA                     NA
  Liver cirrhosis                                                                                                 
   Absent                   40             1                                                                      
   Present                  36             1.339 (0.902--3.125)   0.425                    NA                     NA
  Tumor number                                                                                                    
   Solitary                 36             1                                                                      
   Multiple                 40             2.932 (0.856--3.258)   0.258                    NA                     NA
  Tumor size                                                                                                      
   ≤5 cm                    36             1                                                                      
   \>5 cm                   40             1.568 (0.957--2.569)   0.368                    NA                     NA
  Capsular formation                                                                                              
   Presence                 35             1                                               1                      
   Absence                  41             1.654 (1.181--3.544)   **0.039**                1.258 (1.258--3.985)   **0.041**
  Vascular invasion                                                                                               
   Absent                   30             1                                               1                      
   Present                  46             2.802 (1.258--4.533)   **0.013**                2.698 (1.288--5.010)   **0.017**
  Edmondson-Steiner grade                                                                                         
   Low grade (I--II)        45             1                                                                      
   High grade (III--IV)     31             1.398 (0.862--2.358)   0.099                    NA                     NA
  UICC/AJCC stage                                                                                                 
   I                        30             1                                               1                      
   II--III                  46             2.685 (1.658--3.968)   **0.019**                2.125 (1.377--4.457)   **0.022**
  BCLC stage                                                                                                      
   0--A                     37             1                                                                      
   B--C                     39             1.698 (1.212--3.682)   **0.037**                1.525 (1.137--3.878)   **0.046**
  RACO-1 expression                                                                                               
   Low                      24             1                                               1                      
   High                     52             2.388 (1.529--6.587)   **0.019**                2.149 (1.689--5.776)   **0.022**

**Note:** *P*\<0.05 was considered to be statistically significant; significant values are shown in bold.

**Abbreviations:** AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; UICC, International Union for Cancer Control; RACO-1, RING domain AP-1 coactivator-1; HR, hazard ratio; CI, confidence interval; NA, not applicable.

###### 

Univariable and multivariable analysis of factors in training cohort associated with disease-free survival

  Variables                 Patients (n)   Univariable analysis   Multivariable analysis                          
  ------------------------- -------------- ---------------------- ------------------------ ---------------------- -----------
  Gender                                                                                                          
   Female                   24             1                                                                      
   Male                     52             1.258 (0.785--6.125)   0.339                    NA                     NA
  Age (years)                                                                                                     
   ≤60                      60             1                                                                      
   \>60                     16             1.950 (0.818--4.58)    0.415                    NA                     NA
  Liver cirrhosis                                                                                                 
   Absent                   40             1                                                                      
   Present                  36             1.308 (0.785--3.988)   0.329                    NA                     NA
  Tumor number                                                                                                    
   Solitary                 36             1                                                                      
   Multiple                 40             2.058 (0.820--3.158)   0.208                    NA                     NA
  Tumor size                                                                                                      
   ≤5 cm                    36             1                                                                      
   \>5 cm                   40             1.512 (0.688--2.155)   0.312                    NA                     NA
  Capsular formation                                                                                              
   Presence                 35             1                                               1                      
   Absence                  41             1.398 (1.117--3.128)   **0.039**                1.258 (0.689--3.023)   0.089
  Vascular invasion                                                                                               
   Absent                   30             1                                               1                      
   Present                  46             2.125 (1.286--3.786)   **0.018**                2.133 (1.365--4.013)   **0.026**
  Edmondson-Steiner grade                                                                                         
   Low grade (I--II)        45             1                                                                      
   High grade (III--IV)     31             1.188 (0.890--2.318)   0.123                    NA                     NA
  UICC/AJCC stage                                                                                                 
   I                        30             1                                               1                      
   II--III                  46             2.339 (1.205--3.683)   **0.025**                2.056 (1.237--4.384)   **0.037**
  BCLC stage                                                                                                      
   0--A                     37             1                                                                      
   B--C                     39             1.288 (1.012--3.127)   **0.039**                1.512 (1.087--3.233)   **0.041**
  RACO-1 expression                                                                                               
   Low                      24             1                                               1                      
   High                     52             2.072 (1.268--4.658)   **0.011**                2.233 (1.304--4.285)   **0.029**

**Note:** *P*\<0.05 was considered to be statistically significant; significant values are shown in bold.

**Abbreviations:** AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; UICC, International Union for Cancer Control; RACO-1, RING domain AP-1 coactivator-1; HR, hazard ratio; CI, confidence interval; NA, not applicable.
